Retatrutide 10mg – GLP-1 GIP Glucagon Agonist Research

Retatrutide 10mg is an investigational molecule being studied for its activity as a GLP-1 GIP glucagon agonist. It is a single molecule designed to activate three hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, glucagon-like peptide-1 (GLP-1) receptor, and glucagon receptor.

Because of this three-receptor activity, retatrutide is commonly described as a triple hormone receptor agonist. Researchers are studying its potential role in metabolic pathways and several conditions through ongoing clinical research.

What Is Retatrutide?

Retatrutide is an investigational compound developed by Eli Lilly. It is also identified by the research code LY3437943.

Unlike medicines that primarily activate one or two incretin-related receptors, retatrutide activates GIP, GLP-1 and glucagon receptors. This unique mechanism is why it is frequently described as a triple agonist.

GLP-1 GIP Glucagon Agonist Explained

The phrase GLP-1 GIP glucagon agonist describes the three receptor pathways targeted by retatrutide.

GLP-1 Receptor

GLP-1 is involved in several physiological processes related to glucose regulation and appetite signaling.

GIP Receptor

GIP is another metabolic hormone involved in glucose and energy-related signaling.

Glucagon Receptor

Glucagon is involved in metabolic regulation and energy balance.

Retatrutide is being studied because a single molecule can activate all three receptor pathways.

Retatrutide and Triple Agonist Research

Retatrutide is often described as a first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist.

Current research is evaluating retatrutide in Phase 3 clinical trials involving obesity, type 2 diabetes and several related conditions.

Researchers are investigating how simultaneous activation of these three receptor pathways may influence metabolic processes.

Retatrutide 10mg Research

Retatrutide 10mg is a commonly used product-search term for research materials marketed under the retatrutide name.

For any research product page, the exact strength, formulation, testing information, batch documentation and intended use should be verified against the manufacturer's documentation.

Do not publish laboratory purity, COA, storage or formulation claims unless your actual product documentation supports them.

Retatrutide Research Areas

Current clinical research involving retatrutide includes investigation into:

• Obesity and overweight
• Type 2 diabetes
• Metabolic health
• Cardiometabolic outcomes
• Knee osteoarthritis pain
• Obstructive sleep apnea
• Metabolic dysfunction-associated steatotic liver disease
• Cardiovascular and renal outcomes

These are research areas, not claims that an unapproved product treats or cures these conditions.

Why Is Retatrutide Called a Triple Agonist?

Retatrutide is called a triple agonist because it acts on three receptor systems:

GIP + GLP-1 + Glucagon

This is different from the informal term “GLP-3.” Lilly specifically notes that “GLP-3” is not a scientifically accurate classification; triple agonist is the more appropriate description.

Retatrutide and Metabolic Research

One of the major areas of interest surrounding retatrutide is metabolic research.

Researchers are studying how combined GIP, GLP-1 and glucagon receptor activity may influence metabolic pathways, glucose regulation and energy balance.

The ongoing clinical development program is designed to evaluate both the potential benefits and safety profile of retatrutide.

Product Information

Specification

Details

Product

Retatrutide

Research Code

LY3437943

Strength

10mg*

Classification

Investigational triple agonist

Receptor Targets

GIP, GLP-1 & glucagon

Research Category

Metabolic research

Intended Use

Follow actual manufacturer documentation

*Verify the exact strength against your product's official documentation.

Frequently Asked Questions

What is a GLP-1 GIP glucagon agonist?

A GLP-1 GIP glucagon agonist refers to a compound that activates the GLP-1, GIP and glucagon receptor pathways. Retatrutide is being studied as a triple hormone receptor agonist targeting these three systems.

What is retatrutide?

Retatrutide is an investigational molecule developed by Eli Lilly and also known by the research code LY3437943.

What receptors does retatrutide activate?

Retatrutide activates the GIP receptor, GLP-1 receptor and glucagon receptor.

Why is retatrutide called a triple agonist?

It is called a triple agonist because one molecule activates three hormone receptor pathways: GIP, GLP-1 and glucagon.

Is retatrutide approved for public use?

No. As of August 2026, Lilly describes retatrutide as investigational and states that it has not been approved by a regulatory agency.

What is LY3437943?

LY3437943 is the development/research code used for retatrutide.

Research Disclaimer

Retatrutide is an investigational molecule and is not currently approved for public use. This page is provided for educational and research-information purposes only. It is not medical advice and should not be interpreted as an indication that retatrutide is approved to diagnose, treat, cure or prevent any disease. Do not use products claiming to contain retatrutide outside an authorized clinical-trial setting.

Lilly currently states that retatrutide is legally available only to participants in its clinical trials and warns about unapproved products sold outside those trials.